This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
New Strong Sell Stocks for January 6th
by Zacks Equity Research
AVNS, ALG and CLMB have been added to the Zacks Rank #5 (Strong Sell) List on January 6th, 2026.
New Strong Sell Stocks for Dec. 17
by Zacks Equity Research
AVNS, ADM and OZK have been added to the Zacks Rank #5 (Strong Sell) List on Dec. 17, 2025.
Why Is Avanos Medical (AVNS) Down 0.5% Since Last Earnings Report?
by Zacks Equity Research
Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Avanos Medical Gains on Q3 Earnings Beat, Raises '25 Sales View
by Zacks Equity Research
Avanos Medical posts a Q3 earnings and sales beat, boosts 2025 outlook as Specialty Nutrition drives solid double-digit growth.
Avanos Medical (AVNS) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of +37.50% and +6.88%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Veracyte (VCYT) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Veracyte (VCYT) delivered earnings and revenue surprises of +59.38% and +5.50%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Avanos Medical Buys Nexus Medical to Bolster Critical Care Portfolio
by Zacks Equity Research
AVNS acquires Nexus Medical, adding its TKO connector to expand critical care offerings and drive immediate revenue and earnings growth.
Reasons to Retain Avanos Medical Stock in Your Portfolio Now
by Zacks Equity Research
AVNS's solid Q2 performance, strong product demand, and strategic transformation support growth amid tariff and FX headwinds.
Avanos Medical Stock Down as Q2 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
AVNS shares dip 12% as Q2 earnings miss estimates, margins shrink, and tariff pressures weigh on profitability.
Avanos Medical (AVNS) Misses Q2 Earnings Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of -5.56% and +4.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?